Poussot named chairman of Wyeth

Wyeth announced that Bernard Poussot, 56, its president and CEO, has assumed the additional position of chairman of the board.

Boehringer Ingelheim GmbH said its chief executive officer, Alessandro Banchi, will retire from his post at the end of the year and Andreas Barner, currently deputy CEO, will replace him.

Welichem Biotech has appointed Dr. Genhui Chen as president and CEO. York Yingping Guo resigned as president and CEO for personal and family reasons.

Akesis Pharmaceuticals has appointed Carl LeBel as its new president and COO.

IBT Laboratories announced that Maureen Loftus has joined the company as president and chief operating officer.

Tobira Therapeutics has named the following to its executive team: Sandra Palleja, MD, executive vice-president and chief medical officer, Angeline Shashlo, RPh, senior vice-president regulatory affairs and quality assurance, and Jay Rheingold, PhD, vice-president chemistry manufacturing and controls.

Rosetta Genomics has announced the resignation of Tamir Kazaz, the company's chief financial officer.

Covidien has appointed Michael Giuliani as vice president of research and development for pharmaceutical products and imaging solutions. The company also announced the appointment of James Young as vice president of research and development operations for pharmaceutical products and imaging solutions and Ralph Heasley as vice president of global R&D technology, pharmaceutical products.

Ikaria Holdings has named Deborah Petrowsky, M.D., F.C.C.P.  as vice president for medical affairs and Steven Knapp, M.S., Pharm.D. was appointed vice president of regulatory affairs.

Prime Therapeutics announced the hiring of Jerry Steffl as vice president, government affairs.

Ambrilia Biopharma announced that Jinzi Wu, vice-president of preclinical and basic research, is leaving to join a U.S. pharma company.

Noven Pharmaceuticals named Anthony Venditti as its vice president--marketing & sales.

MDS Pharma Services has named Dr. Patrice Hugo to the position of vice-president of scientific affairs for its global central lab network.

Silence Therapeutics has appointed Annette Clancy and Jerry Randall as non-executive directors and Iain Rugheimer has resigned as a director of the company.

Chelsea Therapeutics International announced that William D. Schwieterman, M.D. has been appointed to the board of directors.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.